<p>随着美国股市在美联储决定降息后出现激增，投资者正在密切关注各个行业的潜在机会。虽然大盘股通常占据头条新闻，但便士股——通常是较小或较新的公司——由于其在稳健财务支持下可能带来的显著回报，仍然引起了人们的兴趣。尽管被视为过去交易日的遗物，便士股仍为那些愿意探索主流之外的投资者提供了引人入胜的前景，其中一些在当今市场环境中展现出令人印象深刻的资产负债表韧性和增长潜力。</p>
<h3>美国十大便士股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>回报与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$450.04M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.82</td>
<td>$632.91M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.93</td>
<td>$152.12M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.25</td>
<td>$545.17M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.37B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.51</td>
<td>$586.77M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>VAALCO Energy (EGY)</td>
<td>$3.53</td>
<td>$369.07M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8977</td>
<td>$6.36M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.20</td>
<td>$100.14M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股筛选器中的 343 只股票的完整列表。</p>
<p>让我们更仔细地看看我们从筛选公司中挑选的几只股票。</p>
<h2>AirJoule Technologies (AIRJ)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> AirJoule Technologies Corporation 专注于大气可再生能源和水收集技术，市值约为 1.784 亿美元。</p>
<p><strong>运营：</strong> AirJoule Technologies 尚未报告任何具体的收入细分。</p>
<p><strong>市值：</strong> $178.4M</p>
<p>AirJoule Technologies 的市值为 1.784 亿美元，尚未产生收入，专注于大气可再生能源和水收集技术。尽管没有债务，但公司的短期资产为 2790 万美元，无法覆盖其长期负债 8440 万美元。董事会和管理层相对较新，平均任期为 1.8 年，表明有潜在的新战略视角，但也缺乏经验。最近的合作包括在德克萨斯州的 Nexus 数据中心进行的一项重要部署，依据水购买协议利用废热进行水生产，符合数据中心运营中的可持续发展趋势。</p>
<ul>
<li>点击探索我们在 AirJoule Technologies 财务健康报告中的详细发现。</li>
<li>查看 AirJoule Technologies 的过去业绩报告，以了解其在往年中的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/44a3d791-28e8-404b-a335-200df617c47b/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/44a3d791-28e8-404b-a335-200df617c47b/chart/financial-position-analysis"/></p>
<p>AIRJ 财务状况分析截至 2025 年 12 月</p>
<h2>AC Immune (ACIU)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> AC Immune SA 是一家临床阶段的生物制药公司，专注于发现、设计和开发与蛋白质错误折叠相关的神经退行性疾病的药物和诊断产品，市值为 2.7605 亿美元。</p>
<p><strong>运营：</strong> 该公司通过发现和开发治疗及诊断产品的细分市场产生收入，金额为 437 万瑞士法郎。</p>
<p><strong>市值：</strong> $276.05M</p>
<p>AC Immune 的市值为 2.7605 亿美元，作为一家尚未产生收入的公司，正在应对神经退行性疾病治疗的挑战。尽管其处于亏损状态，并且最近的收入在 2025 年第三季度下降至 93.9 万瑞士法郎，AC Immune 仍保持无债务状态，并拥有超过一年的现金流。关于 ACI-7104.056 针对帕金森病的积极中期第二阶段数据突显了其管道的潜在进展。最近任命的临床咨询委员会主席 Catherine Mummery 教授为该高风险领域的战略发展提供了丰富的专业知识。</p>
<ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 AC Immune 的动态。</li>
<li>通过我们的公司收益预估报告，获取对 AC Immune 前景和预期表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aeb2912f-ec30-4d4e-aa7e-bc6c0fe03cd7/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aeb2912f-ec30-4d4e-aa7e-bc6c0fe03cd7/chart/financial-position-analysis"/></p>
<p>ACIU 财务状况分析截至 2025 年 12 月</p>
<h2>Erasca (ERAS)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Erasca, Inc. 是一家临床阶段的精准肿瘤学公司，致力于发现、开发和商业化针对 RAS/MAPK 通路驱动癌症的疗法，市值约为 9.249 亿美元。</p>
<p><strong>运营：</strong> Erasca, Inc. 目前未报告任何收入细分。</p>
<p><strong>市值：</strong> $924.9M</p>
<p>Erasca, Inc. 的市值约为 9.249 亿美元，是一家尚未产生收入的临床阶段精准肿瘤学公司，专注于 RAS/MAPK 通路驱动的癌症。该公司最近获得了 ERAS-0015 的美国专利保护，推进了其 RAS 靶向产品线，ERAS-0015 和 ERAS-4001 均处于第一阶段试验中。尽管在 2025 年第三季度报告了 3060 万美元的净亏损，Erasca 仍保持无债务状态，并持有 3.62 亿美元的现金及现金等价物，为其提供了到 2028 年底的财务支持。经验丰富的管理团队和董事会支持公司在股价表现高度波动的情况下的战略进展。</p>
<ul>
<li>点击这里浏览我们关于 Erasca 的全面资产负债表健康报告。</li>
<li>通过我们的详细增长报告评估 Erasca 的未来收益预估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/19d1ebd1-8e07-4de6-802c-563f5ee886d8/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/19d1ebd1-8e07-4de6-802c-563f5ee886d8/chart/financial-position-analysis"/></p>
<p>ERAS 财务状况分析截至 2025 年 12 月</p>
<h2>接下来该如何做？</h2>
<ul>
<li>使用我们的筛选器深入了解所有 343 只美国便士股票。</li>
<li>想探索一些替代方案吗？我们发现 12 只预计明年将支付超过 6% 股息收益率的美国股票。查看完整列表，免费获取。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的完全自主塔。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

ERAS

ACIU

<p>这篇文章强调了在美国股市因降息而上涨的背景下，低价股的投资机会。文章介绍了 AirJoule Technologies、AC Immune 和 Erasca，详细说明了它们的市值、财务健康状况和战略发展。AirJoule 专注于可再生能源，AC Immune 专注于神经退行性疾病，而 Erasca 则专注于肿瘤学。尽管面临挑战，这些公司在各自领域展现出增长和创新的潜力</p>

<p>As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are keenly observing potential opportunities across various sectors. While large-cap stocks often dominate headlines, penny stocks—typically smaller or newer companies—continue to pique interest due to their potential for significant returns when backed by solid financials. Despite being considered a relic of past trading days, penny stocks still offer intriguing prospects for those willing to explore beyond the mainstream, with some demonstrating impressive balance sheet resilience and growth potential in today's market landscape.</p>
<div class="lb-trans"><p>随着美国股市在美联储决定降息后出现激增，投资者正在密切关注各个行业的潜在机会。虽然大盘股通常占据头条新闻，但便士股——通常是较小或较新的公司——由于其在稳健财务支持下可能带来的显著回报，仍然引起了人们的兴趣。尽管被视为过去交易日的遗物，便士股仍为那些愿意探索主流之外的投资者提供了引人入胜的前景，其中一些在当今市场环境中展现出令人印象深刻的资产负债表韧性和增长潜力。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$450.04M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.82</td>
<td>$632.91M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.93</td>
<td>$152.12M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.25</td>
<td>$545.17M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.37B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.51</td>
<td>$586.77M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>VAALCO Energy (EGY)</td>
<td>$3.53</td>
<td>$369.07M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8977</td>
<td>$6.36M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.20</td>
<td>$100.14M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>回报与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$450.04M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.82</td>
<td>$632.91M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.93</td>
<td>$152.12M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.25</td>
<td>$545.17M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.37B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.51</td>
<td>$586.77M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>VAALCO Energy (EGY)</td>
<td>$3.53</td>
<td>$369.07M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8977</td>
<td>$6.36M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.20</td>
<td>$100.14M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 343 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股筛选器中的 343 只股票的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>让我们更仔细地看看我们从筛选公司中挑选的几只股票。</p>
</div><h2>AirJoule Technologies (AIRJ)</h2>
<div class="lb-trans"><h2>AirJoule Technologies (AIRJ)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> AirJoule Technologies Corporation focuses on atmospheric renewable energy and water harvesting technologies, with a market cap of approximately $178.40 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> AirJoule Technologies Corporation 专注于大气可再生能源和水收集技术，市值约为 1.784 亿美元。</p>
</div><p><strong>Operations:</strong> AirJoule Technologies has not reported any specific revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> AirJoule Technologies 尚未报告任何具体的收入细分。</p>
</div><p><strong>Market Cap:</strong> $178.4M</p>
<div class="lb-trans"><p><strong>市值：</strong> $178.4M</p>
</div><p>AirJoule Technologies, with a market cap of US$178.40 million, is pre-revenue and focuses on atmospheric renewable energy and water harvesting technologies. Despite having no debt, the company's short-term assets of US$27.9 million do not cover its long-term liabilities of US$84.4 million. The board and management are relatively new, with an average tenure of 1.8 years, indicating potential for fresh strategic perspectives but also a lack of experience. Recent collaborations include a significant deployment at Nexus Data Centers in Texas under a Water Purchase Agreement to leverage waste heat for water production, aligning with sustainability trends in data center operations.</p>
<div class="lb-trans"><p>AirJoule Technologies 的市值为 1.784 亿美元，尚未产生收入，专注于大气可再生能源和水收集技术。尽管没有债务，但公司的短期资产为 2790 万美元，无法覆盖其长期负债 8440 万美元。董事会和管理层相对较新，平均任期为 1.8 年，表明有潜在的新战略视角，但也缺乏经验。最近的合作包括在德克萨斯州的 Nexus 数据中心进行的一项重要部署，依据水购买协议利用废热进行水生产，符合数据中心运营中的可持续发展趋势。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in AirJoule Technologies' financial health report.</li>
<li>Examine AirJoule Technologies' past performance report to understand how it has performed in prior years.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 AirJoule Technologies 财务健康报告中的详细发现。</li>
<li>查看 AirJoule Technologies 的过去业绩报告，以了解其在往年中的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/44a3d791-28e8-404b-a335-200df617c47b/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/44a3d791-28e8-404b-a335-200df617c47b/chart/financial-position-analysis"/></p>
<p>AIRJ Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>AIRJ 财务状况分析截至 2025 年 12 月</p>
</div><h2>AC Immune (ACIU)</h2>
<div class="lb-trans"><h2>AC Immune (ACIU)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> AC Immune SA is a clinical-stage biopharmaceutical company focused on discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases related to protein misfolding, with a market cap of $276.05 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> AC Immune SA 是一家临床阶段的生物制药公司，专注于发现、设计和开发与蛋白质错误折叠相关的神经退行性疾病的药物和诊断产品，市值为 2.7605 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its segment of discovering and developing therapeutic and diagnostic products, amounting to CHF 4.37 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过发现和开发治疗及诊断产品的细分市场产生收入，金额为 437 万瑞士法郎。</p>
</div><p><strong>Market Cap:</strong> $276.05M</p>
<div class="lb-trans"><p><strong>市值：</strong> $276.05M</p>
</div><p>AC Immune, with a market cap of $276.05 million, is navigating the challenging landscape of neurodegenerative disease treatment as a pre-revenue company. Despite its unprofitability and recent revenue decline to CHF 0.939 million for Q3 2025, AC Immune maintains a debt-free status and has sufficient cash runway for over a year. The positive interim Phase 2 data on ACI-7104.056 for Parkinson’s Disease highlights potential progress in its pipeline. The recent appointment of Prof. Catherine Mummery as Chairwoman of the Clinical Advisory Board brings seasoned expertise to guide strategic development in this high-risk sector.</p>
<div class="lb-trans"><p>AC Immune 的市值为 2.7605 亿美元，作为一家尚未产生收入的公司，正在应对神经退行性疾病治疗的挑战。尽管其处于亏损状态，并且最近的收入在 2025 年第三季度下降至 93.9 万瑞士法郎，AC Immune 仍保持无债务状态，并拥有超过一年的现金流。关于 ACI-7104.056 针对帕金森病的积极中期第二阶段数据突显了其管道的潜在进展。最近任命的临床咨询委员会主席 Catherine Mummery 教授为该高风险领域的战略发展提供了丰富的专业知识。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of AC Immune.</li>
<li>Gain insights into AC Immune's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 AC Immune 的动态。</li>
<li>通过我们的公司收益预估报告，获取对 AC Immune 前景和预期表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aeb2912f-ec30-4d4e-aa7e-bc6c0fe03cd7/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/aeb2912f-ec30-4d4e-aa7e-bc6c0fe03cd7/chart/financial-position-analysis"/></p>
<p>ACIU Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>ACIU 财务状况分析截至 2025 年 12 月</p>
</div><h2>Erasca (ERAS)</h2>
<div class="lb-trans"><h2>Erasca (ERAS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Erasca, Inc. is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, with a market cap of approximately $924.90 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Erasca, Inc. 是一家临床阶段的精准肿瘤学公司，致力于发现、开发和商业化针对 RAS/MAPK 通路驱动癌症的疗法，市值约为 9.249 亿美元。</p>
</div><p><strong>Operations:</strong> Erasca, Inc. currently does not report any revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> Erasca, Inc. 目前未报告任何收入细分。</p>
</div><p><strong>Market Cap:</strong> $924.9M</p>
<div class="lb-trans"><p><strong>市值：</strong> $924.9M</p>
</div><p>Erasca, Inc., with a market cap of approximately US$924.90 million, is a pre-revenue clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers. The company recently secured U.S. patent protection for ERAS-0015, advancing its RAS-targeting franchise with both ERAS-0015 and ERAS-4001 in Phase 1 trials. Despite reporting a net loss of US$30.6 million for Q3 2025, Erasca remains debt-free and holds US$362 million in cash and equivalents, providing financial runway into late 2028. The experienced management team and board support the company's strategic progression amid high volatility in share price performance.</p>
<div class="lb-trans"><p>Erasca, Inc. 的市值约为 9.249 亿美元，是一家尚未产生收入的临床阶段精准肿瘤学公司，专注于 RAS/MAPK 通路驱动的癌症。该公司最近获得了 ERAS-0015 的美国专利保护，推进了其 RAS 靶向产品线，ERAS-0015 和 ERAS-4001 均处于第一阶段试验中。尽管在 2025 年第三季度报告了 3060 万美元的净亏损，Erasca 仍保持无债务状态，并持有 3.62 亿美元的现金及现金等价物，为其提供了到 2028 年底的财务支持。经验丰富的管理团队和董事会支持公司在股价表现高度波动的情况下的战略进展。</p>
</div><ul>
<li>Navigate through the intricacies of Erasca with our comprehensive balance sheet health report here.</li>
<li>Assess Erasca's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里浏览我们关于 Erasca 的全面资产负债表健康报告。</li>
<li>通过我们的详细增长报告评估 Erasca 的未来收益预估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/19d1ebd1-8e07-4de6-802c-563f5ee886d8/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/19d1ebd1-8e07-4de6-802c-563f5ee886d8/chart/financial-position-analysis"/></p>
<p>ERAS Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>ERAS 财务状况分析截至 2025 年 12 月</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该如何做？</h2>
</div><ul>
<li>Get an in-depth perspective on all 343 US Penny Stocks by using our screener here.</li>
<li>Want To Explore Some Alternatives? We've found 12 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>使用我们的筛选器深入了解所有 343 只美国便士股票。</li>
<li>想探索一些替代方案吗？我们发现 12 只预计明年将支付超过 6% 股息收益率的美国股票。查看完整列表，免费获取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的完全自主塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

发现投资机会：AirJoule Technologies 位列三只有潜力的便士股之中